Add this topic to your myFT Digest for news straight to your inbox
Tendering scheme in 11 cities squeezes out anti-cholesterol drug Lipitor
Sales growth and drug approvals accelerate in world’s second-largest market
Big pharma groups make more than $1bn in six months as cheap generics overlooked by prescribers
Expansion of immunisation programmes in developing countries lifts market
Pfizer will probably come up with another big plan. Too bad
Companies take advantage of inflexible patient demand to try to recoup research costs
A good market for pharma buyers means a better market for sellers
Appointed to bring stability, the Pfizer chief is exhibiting a taste for deals
Funding for a mix of behavioural science with checks on the food industry and promotion of healthier lifestyles is crucial
Impending expiries fuel flurry of deals
Looking beyond the rhetoric
Without Lipitor, the company needs to be driven by new drugs that sell
They produce identical drugs, but investors should not treat them all the same
If British drugmaker’s share buy-backs continue, investors should be worried
International Edition